Press releases
- Dexcom Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 9, 2023 at 4:30 p.m. Eastern Time
- Dexcom G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program
- Dexcom Appoints Teri Lawver as Chief Commercial Officer
- Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2022 and Initial 2023 Outlook
- Dexcom to Present at 41st Annual J.P. Morgan Healthcare Conference
- Dexcom Canada Partners With Green Shield and The Health Depot to Offer Plan Members a Comprehensive Digital Diabetes Care Experience
- Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S.
- Truckers’ Health Adaptative Technology (T.H.A.T.) Study Evaluates the Impact of Digital Virtual Models of Care on the Health and Wellbeing of Professional Truck Drivers
- Dexcom Announces Upcoming Conference Presentation
- Dexcom Invites the Diabetes Community to #seediabetes This November and Share Their Diabetes Story With Custom Continuous Glucose Monitor (CGM) Patches
More ▼
Key statistics
As of last trade Dexcom Inc (DC4:FRA) traded at 97.87, -21.34% below its 52-week high of 124.42, set on Oct 31, 2022.
52-week range
Markit short selling activity
Open | 97.87 |
---|---|
High | 97.87 |
Low | 97.87 |
Bid | 98.17 |
Offer | 98.51 |
Previous close | 96.70 |
Average volume | 98.60 |
---|---|
Shares outstanding | 386.26m |
Free float | 384.65m |
P/E (TTM) | 200.03 |
Market cap | 41.36bn USD |
EPS (TTM) | 0.5354 USD |
Data delayed at least 15 minutes, as of Feb 01 2023 07:20 GMT.
More ▼